Endotis Pharma

Endotis Pharma, founded in 2003, is a biotechnology pharmaceutical company dedicated to the research and development of small glycosaminoglycan drugs (SGDs). Their properties (solubility, stability, metabolism...) provide SGDs with many key advantages over other therapies. However, possibly due to the challenges associated with their chemical nature, it is only recently that the pharmaceutical industry has begun to tap into this immense potential; for instance, the antithrombotic drugs Fondaparinux and Idraparinux are derived from heparin.